Histone-modifying enzymes & chromatin state

Histone tails are dynamically marked by writers (HAT/KATs, HMTs/PRMTs, kinases), erased by HDACs/sirtuins and demethylases (KDMs/LSD1), and interpreted by readers (e.g., bromodomains). Together they tune transcription, DNA repair, and cell fate—central to oncology, neuroscience, and immune biology as both mechanisms and druggable nodes.

1. Key targets

Core enzyme families (writers & erasers)

  • HAT / KAT

    p300/CBP, GCN5/PCAF, etc.—H3/H4 acetylation often coupled to activation.

  • HDAC / Sirtuin

    Class I–IV HDACs and NAD⁺-dependent sirtuins mediate deacetylation and complex scaffolding.

  • HMT / PRMT & KDM / LSD1

    EZH2 (PRC2), SET1/MLL, DOT1L, PRMTs vs KDM/JMJD and LSD1 shaping methylation landscapes.

Readers & complexes

  • Bromodomains (BRD2/3/4), YEATS, Tudor domains read acetyl/methyl marks
  • PRC1/PRC2, NuRD, SAGA-like chromatin regulatory assemblies

Example marks

  • H3K4me3、H3K27me3、H3K9me3、H3K36me3
  • H3K27ac、H3K9ac、H4K16ac
  • H2A/H2B variants & ubiquitination (e.g., H2AK119ub)

Supplement: Histone-modifying targets (gene symbols)

HGNC symbols for acetylation, deacetylation, methylation, demethylation, and reader modules.

HAT / KAT

Histone acetyltransferases (HAT/KAT)

EP300, CREBBP, KAT2A, KAT2B, KAT5, KAT6A, KAT6B, KAT7, KAT8

HDAC / Sirtuin

HMT / PRMT

Histone methyltransferases (HMT/PRMT)

EZH2, EZH1, SUZ12, EED, DOT1L, PRMT1, PRMT5, PRMT6, KMT2A, KMT2B, KMT2C, KMT2D, SETD1A, SETD1B, SETD2, SETD7, SUV39H1, SUV39H2

KDM demethylases

Lysine demethylases (KDM)

KDM1A, KDM1B, KDM2A, KDM2B, KDM3A, KDM3B, KDM4A, KDM4B, KDM4C, KDM5A, KDM5B, KDM5C, KDM6A, KDM6B

Readers & complexes

Bromodomain readers

BRD2, BRD3, BRD4, BRDT, BRD9

PRC & complex subunits

RING1, RNF2, BMI1, CBX2, CBX4, CBX7, PHF1, PHF19, EPC1, MTA1, MTA2

2. Suggested experimental readouts

Use mark-specific antibodies with attention to cross-reactivity and fixation; for ChIP/CUT&Tag, pair controls and spike-in where applicable.

  • Total H3/H4 loading controls; pair total-target with modification-specific antibodies
  • Writer/eraser levels & nuclear localization (IF/subcellular fractionation)
  • H3K27ac vs H3K27me3; H3K4me3 vs H3K27me3 dual readouts (lineage/tumor context)
  • Transcriptional validation (RNA-seq, reporter, ChIP-qPCR as appropriate)

3. Writers vs erasers vs readers

ClassExamplesTypical outcomeNotes
Writersp300, EZH2, SETD1B, DOT1L, PRMT5…Install/spread activating or repressive layersSeparate catalytic vs scaffolding roles (complex-dependent)
ErasersHDAC1–3, SIRT1/2, KDM5A, LSD1…Reshape accessibility & expression programsPan-HDACi readouts—pair with isoform context
ReadersBRD4, YEATS2…Recruit transcriptional machinery / condensate-like hubsOften couples to SE–oncogene transcription (models)

4. Disease & research context

  • Cancer: EZH2/DOT1L/BRD4/p300 dysregulation in lymphoid/solid dependencies; combo IO readouts increasingly relevant.
  • Neuro & development: H3K27me3/H3K4me3 balance; MLL-family rearrangements in neurodevelopmental models.
  • Immunity & metabolism: HDAC/SIRT axes shaping T cell differentiation/exhaustion epigenetic programs.

Histone-modifying enzyme–related antibodies (curated)

Loading…

5. Product lines & on-site search

Modification-site & enzyme antibodies

H3K27me3, H3K4me3, H3K9me3, H3K27ac, EZH2, SUZ12, RING1B, HDAC1/2, BRD4, p300—WB/IHC/IF/ChIP-grade per datasheets.

Recombinant proteins & enzyme assays

Histone octamers, mutant substrates, acetyl/methyl donors, and readout kits (availability-dependent).

6. Inhibitors & tool compounds (summary)

For research use; follow lab SOP, compound datasheets, and ethics approvals.

Vorinostat (SAHA)

Pan-HDAC inhibitor; common positive control in epigenetic drug studies.

Panobinostat

Hydroxamate HDACi; hematologic models & combination workflows.

Tazemetostat

EZH2 methyltransferase inhibitor; dependency validation in lymphoid models.

GSK126

Selective EZH2 catalytic inhibitor (tool control).

JQ1 / I-BET151

BET bromodomain antagonists; transcriptional elongation / SE studies.

OG-L002

LSD1-targeting tool compound (project-dependent).

C646

p300 acetyltransferase pocket inhibitor (biochemical/cellular).

Chaetocin

SUVR-family H3K9 methyltransferase inhibitor (toxic—use carefully).

7. Pathway schematic

Histone-modifying enzymes & chromatin control (conceptual)
Histone-modifying enzymes schematic
Legend
  1. Writers install marks on histone tails
  2. Readers bind marks and recruit effectors
  3. Erasers reshape marks and accessibility
  4. Coupling to transcription, replication, repair (context-dependent)

8. Pathway biology overview

Histone marks integrate with DNA methylation, ncRNAs, and chromatin remodelers in a multi-layered epigenetic network. The same mark can be activating or repressive depending on locus and cell state—interpret with lineage cues, signaling inputs, and genome topology (TADs, enhancer–promoter loops).

  • PRC2–H3K27me3 vs trxG–H3K4me3 antagonism recurs in development & cancer
  • Acetyl–bromodomain axes tune rapid stress/inflammatory gene programs

9. Related pathways on this site

Epigenetics (chromatin remodeling, etc.)Cell cycleWnt/β-cateninMAPK/ERKNF-κBTGF-β/SmadPI3K/Akt/mTOR

10. External databases & modification resources

11. References

Reviews & mechanisms

  • • Kouzarides T. (2007). Chromatin modifications and their function. Cell. 128(4):693-705.
  • • Dawson MA, Kouzarides T. (2012). Cancer epigenetics: from mechanism to therapy. Cell. 150(1):12-27.

Enzymes & targeting

  • • Seto E, Yoshida M. (2014). Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 6(4):a018713.
  • • McCabe MT, Creasy CL. (2019). EZH2 as a potential target in cancer therapy. Pharmacol Ther. 190:1-23.